(Total Views: 709)
Posted On: 01/22/2022 10:17:43 PM
Post# of 148902
Ohm,
I agreed with you that it was weird that Cytodyn didn't track the mTNBC patients and their survival rates.
However, what I really meant to agree with was that Cytodyn would have to confirm any of those data with the FDA in an official format. A phone call to Sarah on Elm Street to see if she is alive doesn't pass muster. A verified data point submitted as part of the study concerning Sarah's status would be required, and take a little time post study.
Perhaps, we have now confirmed substantial improvement over SOC in mTNBC in progreesion free and overall survival.
A partnership in Nash would be cool, but its important to remember all of impending catalysts when lamenting the cancelled Investor Relations Conference Call.
chazzle
IMHO
I agreed with you that it was weird that Cytodyn didn't track the mTNBC patients and their survival rates.
However, what I really meant to agree with was that Cytodyn would have to confirm any of those data with the FDA in an official format. A phone call to Sarah on Elm Street to see if she is alive doesn't pass muster. A verified data point submitted as part of the study concerning Sarah's status would be required, and take a little time post study.
Perhaps, we have now confirmed substantial improvement over SOC in mTNBC in progreesion free and overall survival.
A partnership in Nash would be cool, but its important to remember all of impending catalysts when lamenting the cancelled Investor Relations Conference Call.
chazzle
IMHO
(3)
(0)Scroll down for more posts ▼
